Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jason, Exter"'
Autor:
Chibuike J. Alanaeme, Vera Bittner, Todd M. Brown, Lisandro D. Colantonio, Nafeesa Dhalwani, Jenna Jones, Bethany Kalich, Jason Exter, Elizabeth A. Jackson, Emily B. Levitan, Bharat Poudel, Zhixin Wang, Mark Woodward, Paul Muntner, Robert S. Rosenson
Publikováno v:
American Heart Journal Plus, Vol 21, Iss , Pp 100201- (2022)
Study objective: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline recommends a maximally-tolerated statin with add-on lipid-lowering therapy, ezetimibe and/or proprotein convertase subtilisin/kexin ty
Externí odkaz:
https://doaj.org/article/3852eefabfaa4b5e96d2c7e5af5f882f
Autor:
Swati Sakhuja, Vera A. Bittner, Todd M. Brown, Michael E. Farkouh, Emily B. Levitan, Monika M. Safford, Mark Woodward, Ligong Chen, Ruoyan Sun, Nafeesa Dhalwani, Jenna Jones, Bethany Kalich, Jason Exter, Paul Muntner, Robert S. Rosenson, Lisandro D. Colantonio
Publikováno v:
Cardiovascular Drugs and Therapy.
Autor:
Vera Bittner, Emily C. McKinley, Michael E. Farkouh, Stephanie R. Reading, Ligong Chen, Emily B. Levitan, Jason Exter, Monika M. Safford, Lei Huang, Robert S. Rosenson, Kate K. Orroth, Mark Woodward, Lisandro D. Colantonio, Elizabeth A. Jackson, Todd M. Brown, Paul Muntner
Publikováno v:
Cardiovascular Drugs and Therapy. 37:107-116
Adults with atherosclerotic cardiovascular disease (ASCVD) are recommended high-intensity statins, with those at very high risk for recurrent events recommended adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor if thei
Autor:
Alexander R. Zheutlin, Catherine G. Derington, Jennifer S. Herrick, Robert S. Rosenson, Bharat Poudel, Monika M. Safford, Todd M. Brown, Elizabeth A. Jackson, Mark Woodward, Stephanie Reading, Kate Orroth, Jason Exter, Salim S. Virani, Paul Muntner, Adam P. Bress
Publikováno v:
Circulation. Cardiovascular quality and outcomes. 15(12)
Background: Understanding how statins, ezetimibe, and PCSK9i (proprotein convertase subtilisin/kexin type 9 serine protease inhibitors) are prescribed after a myocardial infarction (MI) or elective coronary revascularization may improve lipid-lowerin
Autor:
Erin D. Shannon, Kate K. Orroth, Jason Exter, Katherine E Mues, Robert S. Rosenson, Elizabeth A. Jackson, Paul Muntner, Rebecca Zaha
Publikováno v:
Cardiovasc Drugs Ther
PURPOSE: The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol guideline defines very high atherosclerotic cardiovascular disease (ASCVD) risk as a history of ≥2 major ASCVD events or 1 major ASCVD event and multi
Autor:
Sara N Levintow, Stephanie R Reading, Sina Noshad, Sophie E Mayer, Catherine Wiener, Bassim Eledath, Jason Exter, M Alan Brookhart
Publikováno v:
Clinical Epidemiology.
Sara N Levintow,1,2 Stephanie R Reading,3 Sina Noshad,3 Sophie E Mayer,1,2 Catherine Wiener,1 Bassim Eledath,1 Jason Exter,3 M Alan Brookhart1,4 1NoviSci, Inc., Durham, NC, USA; 2Department of Epidemiology, University of North Carolina at Chapel Hill
Autor:
Christie Ballantyne, Deepak Bhatt, James de Lemos, Qi Gao, Naishu Kui, Robert Rosenson, Katherine Mues, Jason Exter, Shushama Alam, Christopher Cannon, Mikhail Kosiborod
Publikováno v:
Journal of Clinical Lipidology. 16:e37-e38
Autor:
Emily C, McKinley, Vera A, Bittner, Todd M, Brown, Ligong, Chen, Jason, Exter, Michael E, Farkouh, Lei, Huang, Elizabeth A, Jackson, Emily B, Levitan, Kate K, Orroth, Stephanie R, Reading, Robert S, Rosenson, Monika M, Safford, Mark, Woodward, Paul, Muntner, Lisandro D, Colantonio
Publikováno v:
Cardiovascular drugs and therapy.
Adults with atherosclerotic cardiovascular disease (ASCVD) are recommended high-intensity statins, with those at very high risk for recurrent events recommended adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor if thei
Autor:
Jason Exter, Mikhail Kosiborod, Benjamin E Peterson, Shushama Alam, Naishu Kui, Christopher P. Cannon, James A. de Lemos, Christie M. Ballantyne, Deepak L. Bhatt
Publikováno v:
Journal of the American College of Cardiology. 78:B101-B102
Autor:
Nihar R. Desai, Rolin L Wade, Lionel Pinto, Sasikiran Nunna, Xin Wang, Jason Exter, Chi-Chang Chen, Katherine E Mues, Mohdhar Habib, Pin Xiang
Publikováno v:
Clinical Cardiology
Background Low‐density lipoprotein cholesterol (LDL‐C) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). There are limited real‐world data on LDL‐C lowering with evolocumab in United States clinical practice. Hypothesis We